SHANG-YI HUANGChang C.-S.Liu T.-C.Wang P.-N.Yeh S.-P.Ho C.-L.Kuo M.-C.Lin H.-Y.de Jong J.Chen J.-Y.Yang Y.-W.2021-01-122021-01-1220180278-0232https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020545983&doi=10.1002%2fhon.2432&partnerID=40&md5=82f3b81c8be7b02f3a02aaad65a69f78https://scholars.lib.ntu.edu.tw/handle/123456789/540448This phase 4, single-arm, non-randomized, open-label, post approval commitment study evaluated the pharmacokinetics and safety of bortezomib in Taiwanese patients with multiple myeloma. Patients (?20?years) with measurable secretory multiple myeloma (serum monoclonal IgG ?10, IgA/IgE ?5, IgD ?0.5?g/L, IgM present [regardless of level], and urine M protein of ?200?mg/24?h) received intravenous bortezomib 1.3?mg/m2, twice weekly for 2?weeks, followed by a 10-day resting phase (days 12 to 21). Pharmacokinetics and safety were assessed at pre-specified time points. All enrolled patients (n?=?18, men: 11; women: 7) completed the study. Mean (SD) Cmax (maximum observed plasma concentration) on day 11 was 266 (77.5) ng/mL, approximately 60% higher compared with non-Asian patients receiving a similar bortezomib regimen but with overlapping ranges. Because of the protracted terminal phase, half-life (t1/2), area under the plasma concentration-time curve from time 0 to infinity (AUC∞), volume of distribution (Vz), and systemic clearance were not assessable. All patients experienced treatment-emergent adverse events (TEAEs); 78% were drug-related. Most commonly reported TEAEs were thrombocytopenia (n?=?11 [61%]), neutropenia (n?=?9 [50%]), leukopenia (n?=?6 [33%]), and diarrhoea (n?=?6 [33%]); the most common serious adverse event was pneumonia (n?=?2 [11%]). One patient had a dose reduction due to a TEAE of thrombocytopenia. Overall, bortezomib exposure (AUC) in Taiwanese patients (AUClast [SD]: 230 [147]?ng·h/mL) with twice weekly intravenous administration was comparable with non-Asian population (AUClast [SD]: 241 [82]?ng·h/mL). Bortezomib treatment was associated with manageable toxicity profile and did not limit the continuity of therapy. Copyright ? 2017 John Wiley & Sons, Ltd.bortezomib; intravenous; multiple myeloma; pharmacokinetics; safety; Taiwan[SDGs]SDG3bortezomib; antineoplastic agent; bortezomib; adult; aged; anemia; area under the curve; Article; backache; bone pain; cancer chemotherapy; clinical article; decreased appetite; diarrhea; dizziness; drug dose reduction; drug exposure; drug safety; female; fever; headache; heart failure; herpes zoster; human; hyperuricemia; leukopenia; male; middle aged; multiple cycle treatment; multiple myeloma; neutropenia; phase 4 clinical trial; platelet count; pneumonia; priority journal; rhinopharyngitis; Taiwanese; thrombocytopenia; upper respiratory tract infection; volume of distribution; vomiting; clinical trial; intravenous drug administration; multiple myeloma; Taiwan; very elderly; Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Taiwanjournal article10.1002/hon.2432286269472-s2.0-85020545983